Loading...
Market
Major Pharmacies to Prioritize Hyrimoz by End of 2024?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
Public announcements or press releases from major pharmacy chains
Story
CVS Health Replaces Humira with Hyrimoz on April 1, Biosimilar Market Share Surges to 36%
Apr 16, 2024, 02:25 PM
Following a strategic decision by CVS Health, credited by analysts including Elizabeth Anderson from Evercore ISI, there has been a significant increase in the prescription rates of biosimilar versions of Humira, specifically Hyrimoz. CVS Health removed Humira from its major commercial formularies on April 1st and replaced it with Hyrimoz, a biosimilar jointly marketed by its subsidiary Cordavis. This change led to a surge in new prescriptions for Hyrimoz, with the market share of biosimilar versions of Humira jumping from 5% to 36% in just the first week of April.
View original story
Similar markets
Less than 20% • 20%
20% to 35% • 20%
36% to 50% • 20%
51% to 65% • 20%
More than 65% • 20%
CVS • 33%
Walgreens • 33%
Walmart • 34%
FDA confirms significant side effects • 50%
FDA denies significant side effects • 50%